Craft
Pulmonx

Pulmonx

Articles Published

100

Sep, 2020

Revenue

$48.4 M

FY, 2021

Market Capitalization

$644.7 M

2022-09-20

Pulmonx Summary

Company summary

Overview
Pulmonx is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema. It develops the Zephyr Endobronchial Valve, a minimally invasive treatment for chronic obstructive pulmonary disease (COPD). The company also offers the Chartis Pulmonary Assessment system (Chartis System) and the StratX Lung Analysis platform (StratX Platform).
Type
Public
Founded
1998
HQ
Redwood City, CA, US | view all locations
Website
https://pulmonx.com/us/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Glendon E. French

    Glendon E. French, President & CEO

  • Beran Rose

    Beran Rose, Chief Commercial Officer

  • Sri Radhakrishnan

    Sri Radhakrishnan, Chief Technical Officer

  • Derrick Sung

    Derrick Sung, Chief Financial Officer

Operating MetricsView all

Countries Covered (Zephyr Valve)

25

Q2, 2020

Valves Used

80K

Q2, 2020

Patients (Zephyr Valve)

20K

Q2, 2020

LocationsView all

2 locations detected

  • Redwood City, CA HQ

    United States

    700 Chesapeake Dr

  • Neuchâtel, NE

    Switzerland

    Rue de la Treille 4

Pulmonx Financials

Summary financials

Revenue (Q2, 2022)
$14.0M
Gross profit (Q2, 2022)
$10.4M
Net income (Q2, 2022)
($14.6M)
Cash (Q2, 2022)
$121.9M
EBIT (Q2, 2022)
($14.4M)
Enterprise value
$545.0M

Footer menu